恒瑞医疗 网址: www.hrmedical.com.cn

专业文献

deb-ag捕鱼平台

文字: 2017-11-13    浏览次数:939    

purpose  to preliminarily evaluate the clinical efcacy andsafety of drug-eluting bead transarterial chemoembolization (deb-tace) for unresectable soft tissue sarcoma refractory to systemic chemotherapy.

目的  初步评价deb-tace治疗全身化疗疗效欠佳的不可手术切除软组织肉瘤的临床疗效及安全性。


methods  tenpatients with refractory sarcoma who underwent deb-tace therapybetween january2015 and january 2017 were identifed. clinical information and radiological data were retrospectively collected to analyze tumor response,overall survival(os), progression-free survival and adverse events (aes). tumor response to deb-tace was assessed with modifed response evaluation criteria in solid tumors(mrecist) guidelines applied to computed tomography or magnetic resonance imaging.

方法  2015年1月和2017年1月之间筛选10例难治性肉瘤患者,均行deb-tace治疗。收集患者临床资料和放射学资料,分析肿瘤反应、总体生存率(os)、无进展生存率和不良事件(aes)。deb-tace的肿瘤疗效通过ct或磁共振成像,采用改良性实体瘤疗效评价标准评价(mrecist)。


results  all deb-tace procedures were successfully performed for ten patients with 15 tumor lesions. the median follow-up duration was 19 months and the median survival time was 21 months (range 11–30 months). the 1- and 2-year os rate was 90 and30%, respectively.according to the guidance of mrecist, complete response,partial response,stable disease and progressive disease were noted in zero(0%), three (30%),four (40%) and three (30%) patients, respectively. the disease control rate and objective responserate was 70 and 30%, respectively. there were no seriousaes in patients afterdeb-tace.

结果  deb-tace成功治疗10例患者的15个肿瘤病灶。中位随访时间为19个月,中位生存期为21个月(范围为11~30个月)。1年和2年os率分别为90%和30%。根据mrecist评价标准,完全缓解,部分缓解,病情稳定,疾病进展的患者数量分别为0(0%),3(30%),4(40%)和3(30%)。疾病控制率和客观反应率分别为70%和30%。deb-tace治疗后无严重不良反应出现。


conclusions our data showed that deb-tace was efective and safe for patients with soft tissue sarcoma. therefore,deb-tace can be considered as an alternative treatment option for unresectable soft tissue sarcoma refractory to conventionally systemic chemotherapy.

结论  我们的研究数据表明,deb-tace对于软组织肉瘤患者是安全有效的。因此,deb-tace可以作为治疗传统全身化疗效果欠佳的不可手术切除软组织肉瘤的选择方案。